Manav Segal, MD
Allergy & Immunology · Wyndmoor, PANPI 1275747636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,775 of the $51,265 with a category attached, or 93.2%. AstraZeneca accounts for 83.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $18,075 and has fallen 99.9% since, to $19 in 2025. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $582.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43K
- Amgen$8K
- GSK$161
- Optinose US, Inc.$111
- Sanofi-aventis U.S. LLC$65
- Sanofi$37
- plus $110 from 5 others
What the payments were for
- Speaking & faculty fees$47,77593%
- Food & beverage$3,4167%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $42,883 |
| Amgen | 11 | $7,898 |
| GSK | 4 | $161 |
| Optinose US, Inc. | 1 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Sanofi | 2 | $37 |
| Genentech USA, Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,265 in reported general payments places this provider in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 46 | $139,716 |
| Dupixent PenDupilumab | 28 | $103,966 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $93,761 |
| Dupixent SyringeDupilumab | 18 | $73,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $30,040 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $29,372 |
| Spiriva RespimatTiotropium Bromide | 22 | $16,749 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,315 |
| Epinephrine | 45 | $10,161 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $10,125 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $8,866 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,743 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $3,448 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 101 | $3,191 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $161 | $62,460108 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $42,883 | $21,05736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Wyndmoor
- Priya MehtaWyndmoor$18K
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.